Neuropace
NPCE
100 hedge funds and large institutions have $406M invested in Neuropace in 2025 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 37 increasing their positions, 30 reducing their positions, and 4 closing their positions.
550% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 4
52% more capital invested
Capital invested by funds: $268M → $406M (+$138M)
25% more funds holding
Funds holding: 80 → 100 (+20)
23% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 30
0.53% more ownership
Funds ownership: 78.43% → 78.96% (+0.53%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$7.65M |
| 2 |
Walleye Capital
New York
|
+$2.37M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.76M |
| 4 |
JP Morgan Chase
New York
|
+$1.61M |
| 5 |
Jane Street
New York
|
+$1.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$6.77M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.41M |
| 3 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
-$3.02M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$2.93M |
| 5 |
O
OrbiMed
New York
|
-$2.78M |
NPCE Hedge Fund Activity: Q4 2025 in Review
100 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q4 2025, worth a combined $406M — up 52% from $268M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new NPCE positions and 4 closed out — a net gain of 22 holders — while 37 added to existing stakes and 30 trimmed.
The largest buyer was Driehaus Capital Management, adding an estimated $7.65M. The largest seller was Armistice Capital, cutting an estimated $6.77M.
- 100 institutional investors held Neuropace (NPCE) as of Q4 2025, up from 80 in Q3 2025.
- Funds reported $406M of Neuropace stock for Q4 2025, up 52% quarter-over-quarter.
- 26 funds opened new Neuropace positions in Q4 2025 and 4 closed out, a net change of +22 holders.
- The largest Neuropace buyer in Q4 2025 was Driehaus Capital Management, an estimated $7.65M added.
- The largest Neuropace seller in Q4 2025 was Armistice Capital, an estimated $6.77M sold.
Based on aggregated 13F filings for Q4 2025.